Novan, Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for filing Novan's New Drug Application (NDA) seeking approval for berdazimer gel, 10.3% (SB206) for the treatment of molluscum contagiosum (molluscum). The Company also received its Prescription Drug User Fee (PDUFA) goal date of January 5, 2024.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.88% | -99.88% | -99.80% |
Jan. 17 | First Amended Combined Liquidation Plan and Disclosure Statement Filed by NVN Liquidation, Inc. | CI |
2023 | Modified Disclosure Statement Approved on Interim Basis for NVN Liquidation, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+203.83% | 7.06B | |
+2.10% | 982M | |
-3.96% | 954M | |
+41.91% | 872M | |
+22.89% | 800M | |
+1.72% | 664M | |
+7.72% | 659M | |
-.--% | 600M | |
+3.61% | 503M |
- Stock Market
- Equities
- NOVN Stock
- News NVN Liquidation, Inc.
- FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024